Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 8 de 8
4.
J Am Acad Dermatol ; 68(6): 967-71, 2013 Jun.
Article En | MEDLINE | ID: mdl-23374234

BACKGROUND: Mycosis fungoides (MF) is often associated with eosinophilia and portends a poorer prognosis. MF is more common in blacks and follows a more aggressive course compared with whites. OBJECTIVE: We further elucidate racial differences between blacks and whites with MF, focusing on blood eosinophilia. METHODS: The records of 345 patients with MF were reviewed for demographic, clinical, and pathologic data and evaluated by analysis of variance. RESULTS: The average age at diagnosis for blacks was 45 years and was 55 years for white patients (P < .001). In the cohorts of patients with and without blood eosinophilia, the average maximum blood eosinophil count had a greater range in blacks. Independent of race, blood eosinophilia was predictive of more advanced disease (P < .0001), increased number of treatment types (P < .002), and less responsiveness to treatment (P < .0006). LIMITATIONS: This was a retrospective study at a single institution. CONCLUSIONS: These differences observed in eosinophil values may highlight disparities in MF diagnosis or a difference in pathophysiology between races.


Black or African American , Eosinophilia/ethnology , Mycosis Fungoides/ethnology , Skin Neoplasms/ethnology , Adult , Dermatitis, Exfoliative/ethnology , Female , Humans , Male , Middle Aged , Prognosis , Retrospective Studies , White People
5.
Am J Clin Oncol ; 36(5): 481-5, 2013 Oct.
Article En | MEDLINE | ID: mdl-22706179

OBJECTIVE: To determine whether clinical response to total skin electron beam (TSEB) and relapse after TSEB differs by ethnicity and sex. METHODS: Retrospective chart review of 77 patients with mycosis fungoides (MF), treated with TSEB in 2002 to 2008 at Yale University School of Medicine, Departments of Dermatology and Therapeutic Radiology. RESULTS: Women had better odds of response to TSEB than men (OR=6.4; 95% CI, 1.45-28.5; P=0.01). No significant difference was observed in response to TSEB between white and black patients (OR=0.69; 95% CI, 0.16-2.91; P=0.62). When stratified by race and sex, in comparison with black females, all other groups had lower odds of complete response (CR) to TSEB: black males (OR=0.39; 95% CI, 0.002-0.70; P=0.03), white females (OR=0.24; 95% CI, 0.02-2.53; P=0.24), and white males (OR=0.06; 95% CI, 0.006-0.60; P=0.02). Clinical CR was significantly predicted by the duration of symptoms (OR=0.98; 95% CI, 0.97-0.99; P=0.01); and nearly significant by clinical stage; stage III to stage I (OR=0.17; 95% CI, 0.02-1.02; P=0.07). Adjuvant treatment, previous treatment, and time from diagnosis to treatment have no significant effect on CR to TSEB. There was no statistically significant association between relapse after treatment and race, sex, clinical stage, or symptom duration. CONCLUSIONS: The odds of achieving a CR to TSEB decrease when diagnosis of MF is delayed and when patients present with advanced-stage disease. Women with MF were more likely to have a CR to treatment, and this response was even more significant in black women.


Electrons , Mycosis Fungoides/radiotherapy , Neoplasm Recurrence, Local/radiotherapy , Skin Neoplasms/radiotherapy , Whole-Body Irradiation , Aged , Female , Follow-Up Studies , Humans , Male , Middle Aged , Mycosis Fungoides/ethnology , Mycosis Fungoides/mortality , Neoplasm Recurrence, Local/ethnology , Neoplasm Recurrence, Local/mortality , Prognosis , Retrospective Studies , Sex Factors , Skin Neoplasms/ethnology , Skin Neoplasms/mortality , Survival Rate
6.
Clin Lymphoma Myeloma Leuk ; 12(5): 291-6, 2012 Oct.
Article En | MEDLINE | ID: mdl-23040434

UNLABELLED: The T- and B-cell cutaneous lymphomas (CLs) are relatively rare, and information regarding clinical presentation and differences among racial groups might be helpful in determining the best course of clinical care. Data from nearly 5000 patients with CL from the SEER (Surveillance, Epidemiology and End Results Program) registry were evaluated. Nonwhite racial groups present with mycosis fungoides (MF) at an earlier age compared with white, and African American (AA) have increased risk of presenting with higher T-stage compared with white patients. These findings have significant implications regarding need for earlier diagnosis and understanding the reasons for racial disparity in age and stage of presentation. BACKGROUND: The incidence of the T- and B-cell CLs has been well documented, but information pertaining to racial incidence by age, and by burden of disease (stage) have not been extensively documented. MATERIALS AND METHODS: The SEER 2004-2008 public use database was investigated. The relative incidence of CL in different races and age groups was examined. Univariate and multivariate stepwise logistic regression was performed for the likelihood of presenting at a higher stage. RESULTS: Of 4496 patients diagnosed with CL between 2004 and 2008; 1713 patients were diagnosed with MF, 1518 with non-MF cutaneous T-cell lymphoma, and 1265 patients with cutaneous B-cell lymphoma. For MF, there was a trend for females to be less likely to present with a higher T-stage (T3-T4) than males (odds ratio [OR], 0.73) on multivariate analysis (P = .06). For race, AA had a significantly increased risk of presenting with higher T-stage (T3-T4) MF (OR, 1.72) on multivariate analysis (P = .02), compared with white patients. For white, AA, Asian/Pacific Islander, and Native American/other/unknown, the mean age at diagnosis was 59.2, 51.5, 51.3, and 53.8. These groups presented at a significantly different age than white (P = .0001, 0.0001, and 0.0006). CONCLUSION: Nonwhite racial groups present with MF at an earlier age compared with white, and AA have increased risk of presenting with higher T-stage compared with white. These findings have significant implications regarding need for earlier diagnosis and understanding the reasons for racial disparity in age and stage of presentation.


Lymphoma, B-Cell/epidemiology , Lymphoma, T-Cell, Cutaneous/epidemiology , Age Factors , Female , Humans , Incidence , Logistic Models , Lymphoma, B-Cell/ethnology , Lymphoma, B-Cell/pathology , Lymphoma, T-Cell, Cutaneous/ethnology , Lymphoma, T-Cell, Cutaneous/pathology , Male , Middle Aged , Multivariate Analysis , Risk Factors , SEER Program , Sex Factors , United States/epidemiology
7.
J Am Acad Dermatol ; 60(3): 359-75; quiz 376-8, 2009 Mar.
Article En | MEDLINE | ID: mdl-19231637

Over the past three decades, there has been a marked increase in the incidence of cutaneous T-cell lymphoma (CTCL), with significant differences in the rates of CTCL by race and ethnicity. The overall incidence of CTCL has been shown to be higher among blacks than among whites and other racial groups. In addition, CTCL is thought to follow a more aggressive course in black patients. This article highlights the differences in clinical appearance and response to therapy, and discusses the differential diagnosis of CTCL in skin of color in an attempt to ensure earlier diagnosis and better outcomes for these patients.


Lymphoma, T-Cell/diagnosis , Lymphoma, T-Cell/therapy , Skin Neoplasms/diagnosis , Skin Neoplasms/therapy , Skin Pigmentation , Diagnosis, Differential , Education, Medical, Continuing , Humans
8.
Dermatol Online J ; 14(11): 11, 2008 Nov 15.
Article En | MEDLINE | ID: mdl-19094849

Disseminate and recurrent infundibulofolliculitis (DRIF) is an uncommon pruritic follicular eruption of unknown etiology that is predominantly seen in black men. This condition tends to affect the trunk and upper extremities and is usually unresponsive to local and systemic treatment. Recently, several investigators have reported successful treatment with isotretinoin. Herein, we report a case of a patient with disseminate and recurrent infundibulofolliculitis who was successfully treated with potent topical corticosteroids.


Anti-Inflammatory Agents/therapeutic use , Fluocinonide/therapeutic use , Folliculitis/drug therapy , Adenocarcinoma/complications , Administration, Cutaneous , Aged , Anti-Inflammatory Agents/administration & dosage , Back , Diagnosis, Differential , Eczema/diagnosis , Emollients/administration & dosage , Emollients/therapeutic use , Fluocinonide/administration & dosage , Folliculitis/complications , Folliculitis/diagnosis , Folliculitis/pathology , Humans , Hypertension/complications , Lymphocytes/pathology , Male , Prostatic Neoplasms/complications , Pruritus/etiology
...